Type I and Type III Interferons Differ in Their Adjuvant Activities for Influenza Vaccines.
Adaptive Immunity
/ immunology
Adjuvants, Immunologic
Animals
Antibody Formation
/ immunology
Cytokines
Disease Models, Animal
Female
Immunity, Mucosal
/ immunology
Immunization
Immunoglobulin A
/ immunology
Immunoglobulin G
/ immunology
Immunoglobulins
/ genetics
Influenza Vaccines
/ immunology
Interferon Type I
Interferons
/ genetics
Mice
Mice, Inbred C57BL
Mice, Knockout
Orthomyxoviridae Infections
/ virology
Receptors, Cytokine
/ genetics
Vaccination
Interferon Lambda
Thymic Stromal Lymphopoietin
immunization
interferons
mucosal adjuvants
Journal
Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724
Informations de publication
Date de publication:
01 12 2019
01 12 2019
Historique:
received:
30
07
2019
accepted:
05
09
2019
pubmed:
13
9
2019
medline:
17
6
2020
entrez:
13
9
2019
Statut:
epublish
Résumé
Type I and type III interferons (IFNs) can promote adaptive immune responses in mice and improve vaccine-induced resistance to viral infections. The adjuvant effect of type III IFN (IFN-λ) specifically boosts mucosal immunity by an indirect mechanism, involving IFN-λ-induced production of thymic stromal lymphopoietin (TSLP), a cytokine that activates immune cells. To date, it remained unclear whether the previously described adjuvant effect of type I IFN (IFN-α/β) would also depend on TSLP and whether type I IFN stimulates different antibody subtypes. Here, we show that after infection with a live attenuated influenza virus, mice lacking functional type I IFN receptors failed to produce normal amounts of virus-specific IgG2c and IgA antibodies. In contrast, mice lacking functional IFN-λ receptors contained normal levels of virus-specific IgG2c but had reduced IgG1 and IgA antibody levels. When applied together with protein antigen, IFN-α stimulated the production of antigen-specific IgA and IgG2c to a greater extent than IgG1, irrespective of whether the mice expressed functional TSLP receptors and irrespective of whether the vaccine was applied by the intranasal or the intraperitoneal route. Taken together, these results demonstrate that the adjuvant activities of type I and type III IFNs are mechanistically distinct.
Identifiants
pubmed: 31511392
pii: JVI.01262-19
doi: 10.1128/JVI.01262-19
pmc: PMC6854507
pii:
doi:
Substances chimiques
Adjuvants, Immunologic
0
Cytokines
0
Immunoglobulin A
0
Immunoglobulin G
0
Immunoglobulins
0
Influenza Vaccines
0
Interferon Type I
0
Receptors, Cytokine
0
Tslpr protein, mouse
0
Interferons
9008-11-1
Interferon Lambda
0
Thymic Stromal Lymphopoietin
GT0IL38SP4
TSLP protein, mouse
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2019 American Society for Microbiology.
Références
J Virol. 2004 Dec;78(23):13037-45
pubmed: 15542655
Nat Rev Immunol. 2019 Oct;19(10):614-625
pubmed: 31201377
Blood. 2009 Jun 4;113(23):5868-77
pubmed: 19304955
J Exp Med. 2017 May 1;214(5):1529-1546
pubmed: 28428203
Immunity. 2014 Jun 19;40(6):949-60
pubmed: 24909887
J Gen Virol. 1987 Mar;68 ( Pt 3):945-8
pubmed: 3029315
Immunity. 2014 Jun 19;40(6):961-73
pubmed: 24909889
Elife. 2018 Apr 13;7:
pubmed: 29651984
J Immunol. 2002 Jul 1;169(1):375-83
pubmed: 12077267
J Virol. 2017 Mar 13;91(7):
pubmed: 28077656
J Interferon Cytokine Res. 2012 Jun;32(6):235-47
pubmed: 22490303
Nat Immunol. 2019 Aug;20(8):1035-1045
pubmed: 31235953
J Gen Virol. 2009 Dec;90(Pt 12):2990-4
pubmed: 19726611
Annu Rev Immunol. 2005;23:307-36
pubmed: 15771573
J Immunol. 2006 Feb 15;176(4):2074-8
pubmed: 16455962
Sci Immunol. 2016 Oct 21;1(4):
pubmed: 27868108
Genes Immun. 2009 Mar;10(2):125-31
pubmed: 18987645
Viral Immunol. 2017 Oct;30(8):601-614
pubmed: 28650722
Vaccine. 2009 Aug 27;27(39):5344-8
pubmed: 19607949
Sci Immunol. 2016 Oct;1(4):
pubmed: 27812556
J Immunol. 2006 Apr 1;176(7):4343-51
pubmed: 16547272
J Exp Med. 2010 Jul 5;207(7):1485-500
pubmed: 20566717
PLoS Pathog. 2008 Mar 14;4(3):e1000017
pubmed: 18369468
Vaccine. 2008 Feb 26;26(9):1243-52
pubmed: 18243429
Proc Natl Acad Sci U S A. 2007 Apr 17;104(16):6806-11
pubmed: 17426143
Eur J Immunol. 2012 Feb;42(2):353-63
pubmed: 22057556
Sci Immunol. 2016 Oct 21;1(4):
pubmed: 27872905
Vaccine. 2005 Apr 27;23(23):2994-3004
pubmed: 15811645
Nat Immunol. 2019 May;20(5):593-601
pubmed: 30886417
Immunity. 2001 Apr;14(4):461-70
pubmed: 11336691
Immunity. 2009 Sep 18;31(3):491-501
pubmed: 19733096